Hyperlipidemia, Familial CombinedHyperlipidemiasTriglyceridesHypolipidemic AgentsLipidsCholesterolHypertriglyceridemiaCholesterol, LDLHyperlipoproteinemia Type IVLipoproteinsApolipoproteins EHypercholesterolemiaLipid MetabolismRisk FactorsApolipoproteins BCholesterol, HDLApolipoproteins CApolipoprotein E2Apolipoprotein C-IIIFenofibrateLipoprotein LipaseXanthomatosisLipoproteins, VLDLAnticholesteremic AgentsArteriosclerosisHydroxymethylglutaryl-CoA Reductase InhibitorsObesityApolipoproteinsLiverLipoproteins, LDLCholesterol, VLDLGynostemmaHyperlipoproteinemia Type IIDiabetes MellitusDietary FatsReceptors, LDLAtherosclerosisHyperlipoproteinemia Type IIIHypertensionPoloxamerBlood GlucoseHeptanoic AcidsDiabetes Mellitus, Type 2Diet, AtherogenicApolipoprotein A-ICholesterol, DietaryMice, Inbred C57BLPrevalenceCardiovascular DiseasesPostprandial PeriodDyslipidemiasInsulin ResistanceFatty LiverBody WeightBezafibrateEpichlorohydrinSimvastatinApolipoproteins AHyperlipoproteinemiasInsulinTime FactorsDisease Models, AnimalPyrrolesPhytotherapyNephrotic SyndromeCross-Sectional StudiesSex FactorsHyperlipoproteinemia Type VTreatment OutcomeDietFatty Acids, NonesterifiedApolipoprotein E3Mice, KnockoutHyperglycemiaGemfibrozilGadiformesQuestionnairesPravastatinApolipoprotein B-48Lipoproteins, IDLDiabetes ComplicationsChylomicronsUnited StatesRetrospective StudiesDiet, High-FatApolipoprotein A-IILipaseUpstream Stimulatory FactorsJapanApolipoprotein B-100Hyperlipoproteinemia Type IPlant ExtractsRisk AssessmentPhenotypeCoronary DiseaseRegression AnalysisComorbidityChinaProspective StudiesCohort Studies